Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List")

Author(s):  Allen Loyd V Jr, Ashworth Lisa D

Issue:  Jan/Feb 2005 - Sterile Preparations
View All Articles in Issue

Page(s):  44-46

The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the

Download in electronic PDF format for $75

Abstract:  The Food and Drug Modernization Act of 1997 included a provision that the Food and Drug Administration (FDA) compile a list of drugs not to be compounded for humans for reasons of safety. This list came to be called the “negative list.” The list of 59 drugs was published in the Federal Register on March 8, 1999, with the intent that the list would be updated and published regularly. Although the compounding provisions in the Modernization Act were struck down in 2002, it can be argued that the list is still enforceable by the FDA, since it is included in the Compliance Policy Guidelines (CPG) of the Center for Drug Evaluation and Research (CDER). Confusingly, however, in its 2003 Report to the Nation, a different set of “safety-based withdrawals” appears.

Related Keywords: Loyd V. Allen, Jr, PhD, RPh, Lisa D. Ashworth, RPh, Food and Drug Administration, FDA, withdrawn drugs, discontinued drugs, Center for Drug Evaluation and Research, CDER, Compliance Policy Guidelines, CPGs, drug safety

Related Categories: LEGAL, DISCONTINUED FORMULATIONS, FDA

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List")
Allen Loyd V Jr
, Ashworth Lisa D
Jan/Feb 2005
Pg. 44-46

U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Nov/Dec 2016
Pg. 457-458

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
Sep/Oct 2021
Pg. 358-362

Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers
Allen Loyd V Jr
, Williams LaVonn A
Jul/Aug 2012
Pg. 294-298

U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Blankenship Cynthia E
Sep/Oct 2014
Pg. 379-380

PreScription: Discontinued Drugs and Drug Shortages
Allen Loyd V Jr
Mar/Apr 2011
Pg. 92

Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390

Basics of Compounding: The Revised "Not to Compound List"
Allen Loyd V Jr
Jan/Feb 2015
Pg. 57-58

Basics of Compounding: The "Negative" List
Allen Loyd V
Jul/Aug 2015
Pg. 311-313

Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
Jan/Feb 2020
Pg. 30-36

The "Lists": What Do They Mean?
Voliva John
Nov/Dec 2016
Pg. 477-479

PostScription: Drug Shortages and Discontinued Drugs: Their Effects on Healthcare
Allen Loyd V Jr
, Williams LaVonn A
Jul/Aug 2012
Pg. 350-351

PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse
Williams LaVonn A
Nov/Dec 2011
Pg. 526-527

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products
Uttaro Elizabeth
, Zhao Fang, Schweighardt Anne
Sep/Oct 2021
Pg. 364-371

Return to Top